Drug data last refreshed 4d ago · AI intelligence enriched 1w ago
EXOSURF NEONATAL is an intratracheal suspension approved in 1990 for neonatal respiratory distress syndrome, a critical condition in premature infants. The product is a synthetic pulmonary surfactant replacement therapy administered directly into the lungs to restore surface-active properties and improve respiratory function. It represents a foundational therapeutic approach in neonatal critical care.
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating potential team downsizing and transition to generic/maintenance phase activities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on EXOSURF NEONATAL offers limited growth opportunities given its LOE-approaching status and zero currently linked job postings. Career progression is more likely in transition, portfolio, or legacy product management roles rather than expansion or launch activities.
Worked on EXOSURF NEONATAL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.